Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 471 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups
Patents for C07D 471 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups (64,559)
10/2004
10/28/2004CA2521678A1 Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
10/28/2004CA2521619A1 Aminoquinoline compounds
10/28/2004CA2521364A1 [c]-fused bicyclic proline derivatives and their use for treating arthritic conditions
10/28/2004CA2521300A1 Beta-carbolines useful for treating inflammatory disease
10/28/2004CA2520785A1 Substituted 7-aza-quinazoline compounds
10/28/2004CA2520259A1 Cxcr4 chemokine receptor binding compounds
10/27/2004EP1471068A1 Process for total synthesis of ecteinascidins and intermediates therefor
10/27/2004EP1471066A1 Triaza- and tetraaza-anthracenedione derivates, their preparation and their use as pharmaceuticals
10/27/2004EP1471055A1 6-phenylpyridyl-2-amine derivatives
10/27/2004EP1470126A1 N-substituted spiropiperidine compounds as ligands for orl-1 receptor
10/27/2004EP1470125A1 Aminopiperidine derivatives
10/27/2004EP1470124A1 2-(PYRIDIN-2-YLAMINO)-PYRIDO 2,3-d]PYRIMIDIN-7-ONES
10/27/2004EP1470123A1 Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, related compositions and methods
10/27/2004EP1470121A1 Pyrimidine derivatives as rho-kinase inhibitors
10/27/2004EP1469854A1 Condensed heterocyclic compounds
10/27/2004EP1469849A1 Treating stress response with chemokine receptor ccr5 modulators
10/27/2004EP1469810A2 Compositions and methods for prevention and treatment of amyloid-beta peptide-related disorders
10/27/2004EP1212269B1 Methods for preparing n- (aliphatic or aromatic)carbonyl)]-2-aminoacetamide compounds and for cyclizing such compounds
10/27/2004EP1105391B1 Imidazo[1,2-a]pyridine compounds that inhibit gastric acid secretion, pharmaceutical compositions thereof, and processes for thier preparation
10/27/2004CN1541278A Novel molecular target for neurotoxicity
10/27/2004CN1541217A Chemical compounds
10/27/2004CN1541216A 8-methoxy-(1,2,4) triazolo (1,5-A) pyridine derivatives and their use as adenosine receptor ligands
10/27/2004CN1541097A 2-amino-4, 5-trisubstituted thiazolyl derivatives
10/27/2004CN1539843A **Tc marked dopamine transport protein developer
10/27/2004CN1172917C Steroid receptor modulator compounds and methods
10/26/2004US6809199 (Halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents
10/26/2004US6809112 Administering a sexually therapeutically effective amount of a compound having the formula like (5r)-5-(methylamino)-5,6-dihydro-4h-imidazo(4,5,1-ij)quinoline-2(1h)-thione
10/26/2004US6809108 Selective muscarinic m3 receptor antagonts; reduced side effects
10/26/2004US6809105 Diazabicyclic central nervous system active agents
10/26/2004US6809104 Comprises 6h-pyrido(4,3-b)carbazole-containing compounds for treatment of obesity, eating/anxiety/mood disorders and other diseases mediated by g-protein-coupled-receptors and melanin-concentrating hormone receptors
10/26/2004US6809103 E-ring expanded camptothecin derivatives
10/26/2004US6809099 Saframycins, analogues and uses thereof
10/26/2004US6809097 Antiangiogenic and/or vascular permeability
10/26/2004US6809096 Such as 11-methoxy-7h-pyrido(4,3,2-de)(1,7)phenanthroline-7-one; antitumor agents
10/26/2004US6809094 N-fused hetercyclo-1,4- or -1,5- diazabicyclo derivatives; nicotinic receptor agonists; central nervous system (cns)
10/26/2004US6809087 Sodium salt of 2-hydroxy-5-((4-(3-(4-((2-methyl-1h-imidazo-(4,5-c)pyridin-1-yl)methyl)-1 -piperidinyl)-3-oxo-1-phenyl-1-propenyl)phenyl)azo)benzoic acid; inflammatory bowel disease
10/26/2004US6808939 Ligand for use as tool in diagnostic analysis
10/26/2004CA2127411C Tricyclic derivatives
10/21/2004WO2004089951A1 Imidazopyridine derivatives having an affinity for melanocortin receptors
10/21/2004WO2004089950A1 Tricyclic heteroaromatic compounds
10/21/2004WO2004089949A1 7-([1,4]dioxan-2-yl)-benzothiazole derivatives as adenosine receptor ligands
10/21/2004WO2004089931A1 Substituted pyrazoles
10/21/2004WO2004089915A1 Piperazine derivative renin inhibitors
10/21/2004WO2004089380A2 Pharmaceutical use of fused 1,2,4-triazoles
10/21/2004WO2004089370A1 4-phenyl-piperidine compounds and their use as modulators of opioid receptors
10/21/2004WO2004089366A1 Bicyclic compounds as nr2b receptor antagonists
10/21/2004WO2004089360A1 Polyamine compounds for treating chemokine receptor mediated diseases
10/21/2004WO2004089307A2 Acylated spiropiperidine derivatives as melanocortin-4 receptor agonists
10/21/2004WO2004089304A2 Antiandrogens with marginal agonist activity and methods of use
10/21/2004WO2004069832A3 Antibacterial agents
10/21/2004WO2004058144A3 Antibacterial agents
10/21/2004WO2004047760A3 Novel chemical compounds
10/21/2004WO2004024728A3 Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors
10/21/2004WO2003096980A3 Bicyclic modulators of androgen receptor function
10/21/2004WO2003062241A8 Fused heterocyclic succinimidecompounds and analogs thereof, modulators of nuclear hormone receptor function
10/21/2004US20040209939 Pyrrole derivatives
10/21/2004US20040209932 1,3-substitued cycloalkyl derivatives having acidic, mostly heterocyclic groups; processes for their preparation and their use as pharmaceuticals
10/21/2004US20040209929 Fused heteroaryl carboxylic acids as PPAR agonists
10/21/2004US20040209921 CXCR4 chemokine receptor binding comounds
10/21/2004US20040209915 substituted with an N- (p-hydroxy-alpha-hydroxybenzylaminoalkylpiperidinyloxy- (or -amino-)carbonylamino group; useful for identifying compounds having both beta 2 adrenergic receptor agonist and muscarinic receptor antagonist activity
10/21/2004US20040209903 Substituted 7-azaquinazoline compounds useful as p38 kinase inhibitors
10/21/2004US20040209902 Aminoquinoline compounds
10/21/2004US20040209901 substituted 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds, e.g., 8-(2,6-Difluoro-phenyl)-4-(4-fluoro-2-methyl-phenyl)-2-(2-hydroxy-1-hydroxymethyl-ethylamino)-8H-pyrido[2,3-d]pyrimidin-7-one; CSBP/p38 kinase inhibitors.
10/21/2004US20040209898 preparation of the EPCRS form by heating the Risperidone in an organic solvent(s) followed by subsequent cooling and isolation to get desired polymorph
10/21/2004US20040209897 Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds
10/21/2004US20040209894 e.g., 1-(4-chloroanilino)-4-[2-(pyridin-3-yl)-ethyl]-isoquinoline and 5-[4-(tert-butyl)-anilino]-8-[(6-methoxy-pyridin-3-yl)-methyl]-[1,6]naphthyridine
10/21/2004US20040209892 Heterocyclic compounds and methods of use
10/21/2004US20040209889 N-substituted nonaryl-heterocyclic nmda/nr2b antagonists
10/21/2004US20040209882 e.g., 2-{[4-(Cyclohexylmethyl-amino)-6-(3-fluoro-4-methoxy-phenylamino)-[1,35]triazin-2-ylamino]-methyl}-cyclopentanone; treating unwanted cellular proliferation, an inflammation mediated disease, or a hyperproliferative disease, or modulating a glycosidase enzyme
10/21/2004US20040209874 Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE)
10/21/2004US20040209867 for treatment of disorders (sleeping, feeding) relating to or affected by the 5-HT6 receptor; serotonin receptor antagonists
10/21/2004US20040209866 1,8 Naphthyridine derivatives and their use to treat diabetes and related disorders
10/21/2004US20040209865 use for reducing body weight and treating urinary incontinence; Melanin-concentrating hormone (MCH); 5-(4-chloro-phenyl)-2-[5-(2-pyrrolidin-1-yl-ethoxy)-pyridin-2-yl-ethynyl]-pyridine for example
10/21/2004US20040209864 Substituted heterocycle fused gamma-carbolines
10/21/2004US20040209863 5-chloro-N-(5-chloropyridin-2-yl)-2-[(4-{(Z)-(dimethylamino)[(methylsulfonyl)imino]methyl}benzoyl)amino]benzamide; treating thromboembolic disorders, optionally with other active agents
10/21/2004US20040209860 compounds having a (biphenyl-2-yl)oxycarbonylamino- or (biphenyl-2-yl)aminocarbonylamino-substituted (2-7C)azacycloalkyl or (5-10C)azabicycloalkyl group; and a 2-(4-hydroxyphenyl)-2-hydroxyethylamino group; treating asthma or chronic obstructive pulmonary disease; providing bronchodilation
10/21/2004US20040209798 biodrugs for treatment of lung cancer, glioma, anorexia, hypothyroidism, hyperaldosteronism, H. pylori proliferation, acromegaly, restenosis, Crohn's disease, systemic sclerosis, external and internal pancreatic pseudocysts and ascites
10/21/2004US20040209117 Organic light emitting devices
10/21/2004CA2522214A1 4-phenyl-piperidine compounds and their use as modulators of opioid receptors
10/21/2004CA2521907A1 Bicyclic compounds as nr2b receptor antagonists
10/21/2004CA2521416A1 Polyamine compounds for treating chemokine receptor mediated diseases
10/21/2004CA2521400A1 Piperazine derivative renin inhibitors
10/21/2004CA2521201A1 Substituted pyrazoles for use in the prophylaxis or treatment of a disease which can be influenced by the binding of the substitued pyrazoles to 5ht receptors
10/21/2004CA2520855A1 Imidazopyridine derivatives as melanocortin receptor agonists
10/21/2004CA2520114A1 Acylated spiropiperidine derivatives as melanocortin-4 receptor agonists
10/20/2004EP1468999A1 Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators
10/20/2004EP1467997A1 Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with cyclic amino group
10/20/2004EP1467984A2 Synthesis of 4,5-dihydro-pyrazolo (3,4-c) pyrid-2-ones
10/20/2004EP1467974A1 Benzimidazole derivatives and their use as gnrh antagonists
10/20/2004EP1467970A1 Hydroxynaphthyridinone carboxamides useful as hiv integrase inhibitors
10/20/2004EP1467721A2 Substituted amine derivatives and their use for the treatment of angiogenesis
10/20/2004EP1263725B1 Novel compounds
10/20/2004EP1206473B1 Isomeric fused pyrrolocarbazoles and isoindolones
10/20/2004EP1140941B1 Nitrogen containing heterobicycles as factor xa inhibitors
10/20/2004CN1538959A Fused-polycyclic compounds
10/20/2004CN1538956A Spiro compounds
10/20/2004CN1538836A Substituted amine derivatives and method of use
10/20/2004CN1537852A Anti coxsackie viruse action of quinolixiding kind alkaloid
10/20/2004CN1171887C Respiratory syncytial virus replication inhibitors
10/20/2004CN1171875C Uracil substituted phenyl sulfamoyl carboxamides
1 ... 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 ... 646